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Summary 
In multiple sclerosis (MS) T cells aberrantly recognise self-peptides of the myelin 
sheath and attack the central nervous system (CNS). Antigen-specific peptide 
immunotherapy, which aims to restore tolerance while avoiding the use of non-
specific immunosuppressive drugs, is a promising approach to combat autoimmune 
disease, but the cellular mechanisms behind successful therapy remain poorly 
understood. Myeloid-derived suppressor cells (MDSCs) have been studied 
intensively in the field of cancer and to a lesser extent in autoimmunity. Because of 
their suppressive effect on the immune system in cancer, we hypothesised that the 
development of MDSCs and their interaction with CD4+ T cells could be beneficial for 
antigen-specific immunotherapy. Thus, changes in the quantity, phenotype and 
function of MDSCs during tolerance induction in our model of MS were evaluated. 
We reveal, for the first time, an involvement of a subset of MDSCs, known as 
polymorphonuclear (PMN)-MDSCs, in the process of tolerance induction. PMN-
MDSCs were shown to adopt a more suppressive phenotype during peptide 
immunotherapy and inhibit CD4+ T cell proliferation in a cell contact-dependent 
manner, mediated by arginase-1. Moreover, increased numbers of tolerogenic PMN-
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MDSCs, such as observed over the course of peptide immunotherapy, were 
demonstrated to provide protection from disease in a model of experimental 
autoimmune encephalomyelitis (EAE).  
 
Introduction 
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system where immune cells attack myelinated axons of the brain and spinal cord 1. 
The ideal treatment of MS would be to specifically target the disease-causing 
immune cells without compromising the broader function of the immune system. A 
promising approach to the treatment of MS relies on the use of soluble, synthetic 
peptides, based on the sequence of known disease-associated antigens, to promote 
tolerance induction. In the Tg4 model of experimental autoimmune encephalomyelitis 
(EAE), T cells express a transgenic TCR specific for the immunodominant epitope of 
Myelin Basic Protein, MBPAc1-9 2. The development of induced EAE in this model 
can be prevented by repetitive administration of the cognate peptide 3. This is 
characterised by the induction of anergy in CD4+ T cells and a switch in serum 
cytokines from a dominant IFN-γ response towards IL-10. A dose escalation protocol 
for subcutaneous delivery of the high self-antigen doses, required for effective 
tolerance induction, was shown to be highly effective and safe 4, 5. 
Escalating dose immunotherapy (EDI) leads to an upregulation of co-inhibitory 
molecules including LAG-3, TIGIT, TIM-3 and PD1 on CD4+ T cells 5. Another study 
previously found that expression of TIM-3 on T cells resulted in the increase in a 
population of CD11b+ Ly6G+ cells 6. These innate cells, known as myeloid-derived 
suppressor cells (MDSCs), were first described more than 30 years ago in cancer 
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patients 7. Since then, their detrimental role in cancer has been well characterised. 
These immature myeloid cells accumulate in tumours and contribute highly to 
immune escape by suppressing antigen-specific T cell responses 8, 9. Only more 
recently has a potential beneficial role for MDSCs in autoimmune diseases, including 
Type-1 diabetes 10 and EAE 11 become appreciated, demonstrating that MDSCs can 
limit T cell-mediated pathology and tissue injury. In mice, MDSCs are broadly defined 
as CD11b+ Gr1+ cells. Anti-Gr1 antibodies recognise two targets, LY6G and LY6C. A 
further distinction in MDSC subsets can be made based on their differential LY6G 
and LY6C expression 12. Polymorphonuclear MDSCs (PMN-MDSCs) have a CD11b+ 
LY6G+ LY6Clow phenotype, whereas MDSCs with monocytic morphology (M-
MDSCs) are CD11b+ LY6G– LY6Chi 13. MDSCs use multiple mechanisms to 
suppress T cell proliferation. The majority of studies have found an involvement of 
the enzymes arginase-1 and iNOS in MDSC-mediated suppression of T cells 14, 15. 
More recently, other mechanisms of suppression deployed by MDSCs have been 
revealed, including the production of the enzyme indoleamine 2,3-dioxygenase (IDO) 
and IL-10 16, 17. In addition to these soluble factors, cell surface molecules, including 
PD-L1, Galectin-9, CD40 and CD80, have been suggested to play a role in the 
suppression of T cells,  6, 18-20. Here, we reveal for the first time a previously unknown 
role for PMN-MDSCs in antigen-specific tolerance induction.  
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Materials and Methods 
Mice 
All animal experiments were carried out under a UK Home Office Project Licence 
and approved by the University of Bristol ethical review committee. Mice were bred 
and kept under specific pathogen-free conditions. 
The Tg4 T cell receptor (TCR)-transgenic mouse was described previously 21. CD4+ 
T cells in this model express a Vα4 Vβ8.2 transgenic TCR specific for the acetylated 
nine-residue peptide of MBP (Ac1-9) in the context of I-Au.  
 
Peptides 
MBPAc1-9(4K) (Ac-ASQKRPSQR) and the high affinity analogue MBPAc1-9(4Y) (Ac-
ASQYRPSQR) were custom-synthesized by GL Biochem Shanghai. 
 
Escalating-dose peptide immunotherapy 
For tolerance induction, mice were treated subcutaneous (s.c.) every 3–4 days with 
a total of 6 doses of MBPAc1-9(4Y) in PBS in increasing doses: 0.08μg, 0.8μg, 8μg, 3 
x 80μg. 
 
Flow cytometry analysis 
The following anti-mouse antibodies (Biolegend unless stated otherwise) were used: 
CD4 A700, IL-17A PerCP-Cy5.5 (eBioscience), IFN-γ APC (eBioscience), Foxp3 PE 
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(eBioscience), Ly6G A700, Ly6C APC-Cy7, CD11b PerCP-Cy5.5, Galectin-9 PE, 
CD80 BV421, CD86 BV605, CD40 PE-Cy7, PD-L1 APC, MHCII APC-Cy7. Fixable 
viability dye-eFluor780 (eBioscience) was used to exclude dead cells. Samples for 
intracellular staining were activated with 5 ng/ml PMA (Sigma) plus 500ng/ml 
Ionomycin (Sigma) and Golgi Stop (BD Bioscience) for three hours. Cell proliferation 
dye-ef450 (CPD-ef450, eBioscience) was used to visualize cell divisions or calculate 
division and proliferation indexes. FACS acquisition was performed on an LSR-II flow 
cytometer (Becton-Dickinson) and results were analysed using FlowJo software 
(TreeStar Inc). 
Magnetic cell isolation 
Naïve CD4+ T cells were isolated using the MagniSort™ Mouse CD4 Naïve T cell 
Enrichment Kit (#8804-6824-74) from eBioscience according to the instructions. 
Mouse CD11c+ dendritic cells (DCs) from the spleen were isolated using the CD11c 
Microbeads Kit from MACS Miltenyi (#130-052-001). 
 
3[H]-Thymidine proliferation assay 
For some 3[H]-thymidine proliferation assays, 1x106 splenocytes or 2x105 lymph 
node cells were cultured, in triplicate, with titrated doses of MBPAc1-9(4K) in a 96-well 
round bottom plate. For other experiments, CD4+ T cells were magnetically isolated 
from the spleen and a 3[H]-Thymidine assay was set up with titrated doses of 
MBPAc1-9(4K) and irradiated APCs. Cells were cultured for three days at 37°C in a 
CO2 incubator and 0.5 μCi of 3[H]-Thymidine was added to wells for 16 h before 
measurement using a 1450 Micro-β counter (Wallac). 
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In vitro suppression assay 
PMN-MDSC and antigen-experienced CD4+ T cells (Tag) from MBPAc1-9(4Y)-treated 
mice were FACS sorted. PMN-MDSCs and CD4+ T cells were either co-cultured at a 
ratio of 1:3 together with CD11c+ cells as antigen-presenting cell (APC) in a APC:T 
cell ratio of 1:10 and MBPAc1-9(4K)-peptide (10μg/ml) or at a 1:1 ratio in the presence 
of 1 μg/ml plate-bound anti-CD3 and 2 μg/ml anti-CD28 (both from BioXCell). Both 
CD4+ T cell populations were labelled with cell proliferation dye eFluor®450 before 
co-culture. 1x106 CD4+ T cells were used for the co-culture for four days in a 48-well 
plate or 1x105 T cells in a 96-well plate. Some experiments were performed in the 
presence of neutralising antibodies against: PD-L1, Galectin-9, CD40, CD80, CD86 
(all from Biolegend) and IL-10R (BioXCell). For experiments regarding the effect of 
iNOS and arginase-1, 0.5 mM L-NMMA (Merck) or 0.5 mM BEC (Santa Cruz 
Biotechnology) respectively were added at the beginning of the culture. To 
investigate if the suppressive effect of PMN-MDSC is contact dependent, PMN-
MDSC and CD4+ T cells were separated during the co-culture using a transwell 
assay (Corning). 
 
Induction and evaluation of EAE 
EAE was induced by adoptive transfer of MBPAc1-9-specific Th1 cells. Briefly, Tg4 
splenocytes were cultured for 5 days with 10 μg/ml MBPAc1-9(4K) and 5 ng/ml rmIL-12 
(PeproTech), in the presence or absence of PMN-MDSCs from tolerised Tg4 mice at 
a ratio of 1:3. 20 U/ml rhIL-2 (R&D Systems) was added after 72 h. In vitro-polarized 
Th1 cells (5×106) were transferred into Tg4 animals. EAE was assessed twice daily 
with the following scoring system: 0, no signs; 1, flaccid tail; 2; impaired righting 
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reflex and/or gait; 3, hind limb paralysis; 4, forelimb and hind limb paralysis; 5, 
moribund. 
 
Results 
Increase in M-MDSCs and PMN-MDSCs during EDI 
Two subpopulations of MDSCs are currently defined in mice; monocytic MDSCs (M-
MDSCs) characterised by a CD11b+ Ly6G- Ly6Chigh phenotype and 
polymorphonuclear MDSCs (PMN-MDSCs) that have a CD11b+ Ly6G+ Ly6Clow 
phenotype. We observed that after a course of EDI with MBPAc1-9(4Y) the percentage 
of MDSCs among CD11b+ cells had increased systemically compared to control-
treated animals (Figure 1A). In the spleen, inguinal lymph nodes (ILN), brachial 
lymph nodes (BLN), liver, lung, brain and spinal cord, the increase in the percentage 
of PMN-MDSCs was more pronounced than that of M-MDSCs. The lung was the 
only organ where we observed an increase in the frequency of both MDSC subsets. 
Considering these results, we decided to concentrate on PMN-MDSCs for further 
experiments in which we assessed kinetics of MDSC changes during EDI. 
Expressed as a percentage of all leukocytes, the frequency of PMN-MDSCs peaked 
after the 3rd treatment in most organs other than the liver, where a significant 
increase was not established until the 5th treatment (Figure 1B). These experiments 
did not detect a statistically significant difference in the frequency of PMN-MDSCs in 
the spinal cord. In addition to the frequency of PMN-MDSCs, we also assessed 
absolute cell numbers for each organ (Figure 1C). These revealed a very similar 
pattern to the changes in the percentages.  
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Dose escalation immunotherapy alters PMN-MDSC phenotype 
The pronounced accumulation of PMN-MDSCs after the 3rd dose of peptide 
treatment led us to further investigate PMN-MDSC phenotype and function at this 
point. At this time, CD4+ T cells also start to undergo phenotypic changes that 
characterise the EDI protocol, namely the reduction in effector cytokines and the 
switch to IL-10-production in CD4+ T cells 5. To further characterise the phenotype of 
PMN-MDSCs and find ways in which they might influence the function of CD4+ T 
cells during the course of EDI, we investigated several markers that can affect CD4+ 
T cell activation, including Galectin-9, PD-L1, CD40, CD80 and CD86. 
Representative staining of splenic PMN-MDSCs is shown in Figure 2A. The extent to 
which expression of these markers on PMN-MDSCs was altered by EDI varied 
greatly depending on the location of the cells. For example, Galectin-9, PD-L1 and 
CD86 expression was increased on splenic PMN-MDSC compared to mice receiving 
PBS only as a control (Figure 2B). In other organs, such as the lung, Galectin-9 was 
increased but PD-L1 decreased in comparison to control-treated animals. There was 
no difference in CD40 expression in any of the organs evaluated. CD80 expression 
on PMN-MDSCs trended towards a reduction in MBPAc1-9(4Y)-treated animals but 
this was significant only in the ILNs.  
 
Splenic PMN-MDSC suppress antigen-mediated proliferation of naïve CD4+ T 
cells in vitro 
In order to establish whether the PMN-MDSCs that developed during EDI do indeed 
have immune regulatory properties, we first assessed their effect on CD4+ T cell 
proliferation in vitro. Naïve Tg4 CD4+ T cells (Tnaiv) and antigen-experienced CD4+ 
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T cells (Tag) labelled with cell proliferation dye were co-cultured with CD11c+ APCs 
and 10 μg/ml of cognate peptide, in the presence or absence of PMN-MDSCs from 
tolerised mice. After the four-day co-culture we measured CD4+ T cell proliferation by 
flow cytometry and calculated the proliferation and division indexes. These 
experiments revealed that addition of PMN-MDSCs to the T cell cultures reduced the 
division index of proliferating naïve CD4+ T cell, but to our surprise, PMN-MDSCs 
were unable to reduce the proliferation of CD4+ Tag cells (Figure 3A). Importantly, 
addition of PMN-MDSCs led to the expansion of CD4+ Foxp3+ regulatory T cells 
within the CD4+ T cell population, although this only reached statistical significance 
for the combined data from 5 separate co-cultures with CD4+ Tag cells (Figure 3B). 
This could potentially be explained by the additional requirement of IL-2 for optimal 
CD4+ Treg cell expansion. This cytokine is secreted abundantly by CD4+ Tag cells 
but not naïve CD4+ T cells.    
 
Splenic PMN-MDSC suppress the proliferation of antigen-experienced CD4+ T 
cells activated by a polyclonal stimulus in vitro in a cell-contact dependent 
manner 
Next we sought to determine if, in addition to suppression of an antigen-driven 
response, PMN-MDSC in the Tg4 model could act as suppressors of CD4+ T cell 
proliferation activated in vitro without antigen or APC. Either Tnaiv or Tag cells, 
labelled with proliferation dye, were cultured together with PMN-MDSCs from 
tolerised mice at a ratio of 1:1 for four days on a plate coated with anti-CD3 and anti-
CD28. The suppressive activity of PMN-MDSCs is their main characteristic but to 
make sure that this suppressive ability is the result of tolerance induction through 
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EDI, we also isolated PMN-MDSCs from PBS-treated mice as a control and included 
those in our proliferation assays. PMN-MDSCs from tolerised mice were found to be 
potent suppressors because they reduced the division index of both naïve CD4+ T 
cells and antigen-experienced T cells significantly (Figure 4A+B). On the other hand, 
PMN-MDSCs from control mice were not able to reduce the proliferation. In order to 
determine if the suppressive activity seen before is cell contact-dependent, transwell 
experiments were performed. In these experiments, CD4+ Tag cells were cultured on 
an anti-CD3+anti-CD28-coated plate, separated by a membrane from splenic, 
FACS-sorted PMN-MDSC from tolerised Tg4 mice. Physical separation of PMN-
MDSCs and responder cells abrogated the suppressive effect on CD4+ T cell 
proliferation, which suggested that the PMN-MDSC-mediated suppression of CD4+ T 
cell proliferation is cell contact-dependent (Figure 3C). 
 
PMN-MDSCs use a range of suppressive mechanisms 
Several molecules have previously been suggested to mediate cell contact-
dependent suppression by PMN-MDSCs. To investigate the molecules that may be 
involved in the suppressive effect of PMN-MDSCs, blocking antibodies targeting 
molecules expressed on the surface of PMN-MDSCs, namely Galectin-9, PD-L1, 
CD40, CD80 and CD86, or anti-IL-10R were added to the co-culture. The 
suppressive activity of PMN-MDSCs was impaired under several of these conditions 
(Figure 5A). The addition of either anti-Galectin-9 or PD-L1 alone did not abrogate 
the suppressive activity of PMN-MDSCs whereas the co-blockade of both ligands 
restored CD4+ T cell proliferation at least in part, indicating a synergistic effect of 
Galectin-9 and PD-L1 in CD4+ T cell suppression. The addition of blocking antibodies 
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targeting the surface molecules CD40, CD80 or CD86 restored CD4+ T cell 
proliferation in a similar fashion. IL-10 receptor signalling, however, did not appear to 
be essential for the suppressive activity of PMN-MDSCs because in our in vitro 
suppression assay blockade of IL-10R (Figure 5A) did not alleviate CD4+ T cell 
suppression. In addition to these cell surface antigens, soluble factors may still be 
involved in mediating suppression of CD4+ T cells in close proximity. Therefore, the 
possible role of iNOS and arginase-1 in mediating the suppression of CD4+ T cell 
proliferation was investigated further by the addition of an inhibitor of iNOS, (NG-
monomethyl-L-arginine (L-NMMA), or an inhibitor of arginase-1, (S-(2-boronoethyl)-
L-cysteine (BEC) to the suppression assay (Figure 5B). The addition of the arginase-
1 inhibitor but not iNOS inhibitor abrogated the suppressive effect of PMN-MDSCs.  
 
Frequencies and phenotype of PMN-MDSCs in peripheral organs in diseased 
versus tolerised mice 
The role of MDSCs in autoimmunity remains controversial. On the one hand, the 
accumulation of CD11b+Ly6Chigh M-MDSCs in EAE positively correlated with disease 
severity and an improvement in pathology was accompanied by the reduction of 
these cells 22, 23. However, in contrast to these studies their beneficial role in 
autoimmune diseases including EAE has become increasingly appreciated in recent 
years 11. MDSCs have been shown to be able to limit T cell-mediated pathology and 
tissue injury as a result of their suppressive activity 24. To assess the dynamics of 
PMN-MDSCs during EAE in the TG4 model, mice were treated with MBPAc1-9(4Y) to 
confer protection or with PBS only as a control, prior to the induction of EAE. 
Animals were culled at the peak of disease when PBS-treated animals had an 
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average disease score of 3 with complete hind limb paralysis (typically around day 
14 post immunisation). MBPAc1-9(4Y)-treated animals, which displayed no EAE 
symptoms, were taken at the same time of analysis. This confirmed that the 
frequency of PMN-MDSCs was increased in animals in which EAE was induced 
compared to animals that were not primed for disease (Figure 6A compared to 
Figure 1B). In fact, the frequency of PMN-MDSC in mice with EAE was significantly 
higher in many of the organs examined than in mice that had been tolerised using 
EDI (Figure 6A). This then prompted the question whether qualitative changes may 
be more important for the immunosuppressive of MDSCs than quantitative changes. 
We therefore examined if the PMN-MDSC that arise during the development of EAE 
are phenotypically different from the ones that are generated during tolerisation. 
Indeed, we observed a significant two-fold lower expression of CD40 on PMN-
MDSCs in the spinal cord of mice with EAE compared to tolerised animals (Figure 
6B). Furthermore, we detected a significantly lower expression of CD80 in the CNS 
compartment both in the brain and spinal cord, in tolerised animals compared to 
animals with EAE (Figure 6B). Finally, we found an increased expression of 
Galectin-9 and PD-L1 in both the spleen and lymph nodes in tolerised mice 
compared to control mice. However, the expression levels of these two markers in 
tolerised animals differ greatly between the spleen and inguinal lymph nodes in 
particular (Figure 6B). These findings hint at the possibility that phenotypic 
differences between the PMN-MDSCs that develop after EAE development or after 
tolerisation play a role in their functional dichotomy. 
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Splenectomy impairs the increase in the number of PMN-MDSCs post EDI and 
prevents tolerance induction 
We demonstrated an increase in the number of splenic PMN-MDSCs, with a marker 
profile distinct from PMN-MDSCs residing in the lymph nodes. Therefore, we wanted 
to further investigate the role of the spleen in tolerance induction. To achieve this, we 
performed splenectomies or sham operations prior to tolerance induction in Tg4 mice 
and analysis of the number of PMN-MDSCs in the lymph nodes, lung or liver. As 
shown in Figure 7A+B, splenectomy resulted in a statistically significant abrogation 
of the increase in the percentage of PMN-MDSCs after EDI only in the ILNs, 
although a similar trend was observed in the BLNs and, in particular, the liver. 
Furthermore, we found that an intact spleen was essential for successful tolerance 
induction with MBPAc1-9(4Y). Removal of the spleen did not affect disease 
development in control-treated animals (Figure 7C), whereas animals receiving 
MBPAc1-9(4Y)-treatment after a sham operation were largely protected against the 
induction of EAE. Their splenectomised counterparts all developed severe EAE. In 
order to allow for statistical analysis of the EAE scores of all animals over the course 
of the experiment, the area under the curve (AUC) was calculated and this 
demonstrated the same trend (Figure 7C). 
 
Signalling through the IL-10 receptor controls PMN-MDSC accumulation and 
phenotype 
Our previous data showed that IL-10 receptor signalling is not essential for the 
suppressive activity of PMN-MDSCs because blockade of IL-10R signalling by an 
antibody did not alleviate CD4+ T cell suppression in vitro (Figure 5A). However, we 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
were still interested to know if IL-10 signalling affects the quantity and phenotype of 
PMN-MDSCs. First, we treated Tg4IL-10-/- mice with either PBS or MBPAc1-9(4Y) 
according to the EDI protocol until the 3rd dose before isolating the spleen and lymph 
nodes to determine the quantity of PMN-MDSCs. The significant increase of PMN-
MDSCs that results from peptide treatment in IL-10-sufficient animals was impaired 
in spleen and lymph nodes of Tg4IL-10-/- mice (Figure 8A+B). This was true for both 
the increase in the percentage and absolute number of PMN-MDSCs in the lymph 
nodes (Figure 8A+B). The fact that we detected fewer PMN-MDSCs in IL-10-/- 
animals could be either a direct effect because MDSCs can express IL-10R 25 or an 
indirect effect of excess CD4+ T cell activation in response to antigenic challenge in 
IL-10-/- mice. The reduction in the number of PMN-MDSCs in Tg4IL-10-/- animals led 
us to further characterise the phenotype of PMN-MDSC in this model. The reduction 
of CD80 expression commonly observed in wild-typeTg4 mice after MBPAc1-9(4Y)-
treatment is abrogated in IL-10-/- mice (only statistically significant in the ILNs) 
(Figure 8C). Moreover, the substantial increase of CD86 expression on PMN-
MDSCs from wild-type Tg4 mice in the spleen post EDI was impaired in Tg4IL-10-/- 
mice (Figure 8D). 
 
PMN-MDSCs reduce CD4+ T cell proliferation after antigen challenge in vivo 
In order to test if, in addition to their inhibitory effect in vitro, PMN-MDSCs are able to 
reduce the proliferation of CD4+ T cells in vivo, Tg4 mice received a cell transfer of 
1.5x106 FACS-sorted PMN-MDSC from tolerised mice i.p. three days before priming 
with MBPAc1-9(4K) peptide in complete Freund’s adjuvant (CFA) at the base of the 
tail. Ten days later, spleen and ILNs were harvested and a 3[H]-Thymidine assay 
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was set up. The proliferative response after restimulation in vitro with cognate 
peptide was significantly reduced in cells from the spleen but not the ILNs from mice 
that had received a transfer of PMN-MDSCs compared to mice that did not receive 
PMN-MDSCs (Figure 9A). Next, to exclude the possibility that transferred PMN-
MDSCs still present in the whole splenocyte suspensions mediate suppression of 
CD4+ T cell proliferation at the time of restimulation in vitro, CD4+ T cells were 
magnetically isolated from the spleen and a separate 3[H]-Thymidine assay was set 
up with titrated doses of MBPAc1-9(4K) and irradiated APCs. Again, the proliferation of 
CD4+ T cells isolated from mice that had received a transfer of PMN-MDSCs was 
significantly reduced over a range of MBPAc1-9(4K) peptide concentration compared 
to cells from mice that did not receive the transfer (Figure 9B). In addition, 
intracellular cytokine staining demonstrated a small but not significant reduction in 
the production of the proinflammatory cytokines IFN-γ or IL-17 by CD4+ T cells from 
animals that had received a PMN-MDSC transfer, upon restimulation with 
PMA/Ionomycin (Figure 9C). 
 
PMN-MDSCs ameliorate encephalogenicity of Th1 cells. 
Given the reduction in CD4+ T cell proliferative capacity after adoptive transfer of 
PMN-MDSCs ex vivo, we asked if PMN-MDSCs would interfere with CD4+ T cell 
pathogenicity. Therefore, MBP-specific CD4+ T cells were polarised in vitro under 
normal Th1 conditions either with or without the addition of PMN-MDSCs, prior to 
adoptive transfer to Tg4 recipients to induce a passive form of EAE. The addition of 
PMN-MDSC during Th1 polarisation led to a clear amelioration of EAE severity and 
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to an enhanced recovery from disease, demonstrating their disease-limiting 
propensity (Figure 10 and Table 1).  
 
Discussion 
In this study, we show for the first time that MDSCs, and PMN-MDSCs in particular, 
accumulate during the course of EDI in various organs from the CNS to the 
periphery. The preferential expansion of PMN-MDSCs over M-MDSCs does not 
come as a complete surprise because PMN-MDSCs represent the major pool of 
circulating and expanding MDSCs in both mice and humans in the tumour 
environment 26, revealing a 3:1 ratio of PMN-MDSCs to M-MDSCs 27. The more 
pronounced accumulation of PMN-MDSC after the 3rd dose of peptide treatment may 
result from the fact that Tg4 mice showed a peak in the amount of IL-6 and IL-17 
after this dose 5. These cytokines are known to mediate the accumulation of MDSCs 
and their immunosuppressive function 28-31. The PMN-MDSCs that we induced 
during antigen-specific peptide immunotherapy were able to reduce the proliferation 
of CD4+ T cells and expand CD4+ Foxp3+ T cells in vitro. Moreover, adoptive transfer 
of PMN-MDSCs prior to priming of Tg4 mice with MBPAc1-9(4K) in CFA reduced the 
CD4+ T cell proliferative response upon restimulation ex vivo. We found that PMN-
MDSCs were able to suppress naïve CD4+ T cell proliferation induced by either an 
antigen-specific or non-specific stimulus. Surprisingly, PMN-MDSCs reduced the 
proliferative response of antigen-experienced T cells only when stimulated non-
specifically with anti-CD3+anti-CD28. A previous study showed that MDSCs from the 
tumour site and spleen of the same mouse can differ in their ability to suppress CD8+ 
T cell proliferation even though no phenotypic differences could be detected(31). 
Both MDSC-populations were able to suppress CD8+ T cell proliferation in an 
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antigen-specific manner, however splenic MDSCs did not suppress CD8+ T cell 
proliferation in response to anti-CD3+anti-CD28. These differences in suppression 
could be explained by the tumour environment, where suppressive factors are 
present that are absent in the spleen. But, all PMN-MDSCs we studied were isolated 
from the spleen and only the method of CD4+ T cell stimulation differed. So far, we 
have no definitive explanation as to why in our experiments antigen-experienced 
cells could be suppressed when stimulated with antibody but not when stimulated 
with antigen, but it could have to do with either the affinity of the interaction or the 
involvement of co-stimulatory or co-inhibitory molecules. It further remains to be 
determined if the fact that the antigen-experienced T cells in our experiments have 
had more than one previous antigen encounter affects their ability to be suppressed 
by MDSCs.  
 
Most of the published studies, as well as our own results, indicate that MDSCs need 
direct cell-cell contact to exert their immunosuppressive function, which suggests 
that they act either through cell surface receptor-ligand interactions or through 
release of soluble mediators that act only in close proximity 32. MDSCs have 
previously been shown to use multiple mechanisms to suppress T cell proliferation 
14
. The majority of studies have found an involvement of the enzymes arginase-1 and 
iNOS in MDSC-mediated suppression of T cells 14, 15. However, the addition of an 
inhibitor of iNOS, NG-monomethyl-L-arginine (L-NMMA) did not ablate the 
suppressive activity of PMN-MDSCs in our hands, whereas the arginase-1 inhibitor 
(BEC) restored CD4+ T cell proliferation, thus suggesting a preferential role for 
arginase-1 in our model.  
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It has been suggested that the suppressive activity of MDSCs is dependent on the 
immunomodulatory cytokine IL-10 17 although this finding is not universally supported 
33
. However, signalling through the IL-10-receptor was found to be required to 
establish the suppressive phenotype in MDSCs 33, which supports our findings that 
although addition of a blocking anti-IL-10R antibody did not restore CD4+ T cell 
proliferation, tolerisation of IL-10-deficient animals showed a change in the 
phenotype of PMN-MDSCs compared to IL-10-sufficient mice.  
In addition to these soluble factors, the cell surface molecules PD-L1 and Galectin-9 
have been suggested to mediate the T cell suppressive effect 6, 18. In our study the 
blockade of either cell surface receptor separately during in vitro co-culture using 
neutralising antibodies did not restore T cell proliferation whereas the co-blockade of 
both molecules together led to the abrogation of suppression, indicating a synergistic 
effect. 
The frequency of PMN-MDSC in mice with induced EAE was significantly higher in 
many of the organs examined than in mice that had been protected by EDI. This 
raises the question why animals are not protected from disease even though these 
potentially immunosuppressive PMN-MDSCs arise. Our findings hint at the 
possibility that phenotypic differences between those PMN-MDSCs that develop 
after EAE development and those that arise after tolerisation contribute to their 
functional dichotomy. Compared to the PMN-MDSCs of mice with EAE, we detected 
a higher expression of Galectin-9 and PD-L1 on PMN-MDSCs in the spleen and 
lymph nodes with an increase of CD40 and a decrease of CD80 in the CNS 
compartment of tolerised animals. The exact role of CD40 in MDSC-mediated 
suppression remains unclear but Pan et al. showed that CD40 expressed on MDSCs 
is essential for their suppressive function and T reg cell induction 19. This is 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
supported by our in vitro findings, where blockade of CD40 abrogated PMN-MDSC-
suppression and restored CD4+ T cell proliferation. 
In recent years, the expression of CD80 on MDSCs has been associated with 
immune suppression 20, which corroborates our findings that the addition of anti-
CD80 to our in vitro co-cultures led to abrogation of MDSC-mediated inhibition of 
CD4+ T cell proliferation. This, however, is in direct contrast to our hypothesis that 
peptide treatment promotes a more suppressive PMN-MDSC phenotype in the CNS, 
as we found a reduced expression of CD80 on PMN-MDSCs in the CNS of tolerised 
animals. The effect of CD80 expression on the function of PMN-MDSCs remains 
unclear however, as it was shown previously that, in a rat model of kidney allograft 
tolerance, blood-derived CD80-positive MDSCs have the same suppressive capacity 
as their CD80-negative counterparts 34. Overall, it is unclear how important the 
phenotype of PMN-MDSCs in the CNS is for the prevention of EAE as the 
maintenance of tolerance and prevention of disease development may very well be 
controlled in the periphery rather than the CNS. After all, removal of the spleen 
prevented successful tolerance induction and hence protection from disease. This 
was also shown previously in a model of experimental autoimmune uveoretinitis 
(EAU) where splenectomy likewise abrogated the induction of tolerance 35. 
PD-L1 expression on PMN-MDSCs was increased only in the spleen and no other 
organs of tolerised animals. PD-L1+ PMN-MDSCs could potentially interact with PD-
1-expressing CD4+ T cells in the spleen 5. Tumour-infiltrating MDSCs from tumour-
bearing mice have previously been shown to express high levels of PD-L1 and to be 
able to suppress the proliferation of CD8+ T cells 18. MDSC-mediated T cell 
suppression may thus be mediated by the PD-L1-PD-1 axis and that this interaction 
is likely take to place in the spleen. Another important negative regulator of T cell 
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activity, TIM-3, was significantly upregulated on CD4+ T cells in the spleen of 
tolerised animals that were protected from EAE in our study 5. An earlier study 
described a potential role for the Tim-3/Galectin-9 pathway in MDSC proliferation 6. 
Our results suggest that MDSC-mediated plasticity of conventional T cells in the 
spleen, and not just the differentiation of Treg cells might, at least in part, be 
responsible for the protective effect of EDI. After all, our splenectomy experiments 
showed that animals without a spleen receiving EDI were still more susceptible to 
EAE than mice that retained their spleen. Our findings are supported by a study 
where splenectomy prior to tolerance induction to OVA did not affect the number of 
CD4+ Treg cells yet the establishment of skin tolerance could not be achieved 36. 
Previous work implied that T cells need to migrate through the spleen to become 
encephalitogenic and cause disease, in a process known as T cell licensing 37. One 
could speculate that PMN-MDSCs in the spleen may prevent T cell licensing, 
although this will require further investigation. 
Our work further provides evidence for a direct effect of PMN-MDSCs on the 
encephalogenicity of Th1 cells, as T cells cultured in the presence of PMN-MDSCs 
are less potent inducers of EAE. Animals developed less severe EAE symptoms and 
recovered faster from disease compared to animals that received Th1 cells polarised 
under normal conditions. 
Overall, we demonstrate here that PMN-MDSCs play an important role in tolerance 
induction during antigen-specific immunotherapy of autoimmune disease. Their 
differentiation should therefore be a prime target of treatment and may be an 
indicator of successful therapy. 
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Figure legends 
Figure 1. Increase in M-MDSCs and PMN-MDSCs during EDI. Shown are 
representative FACS plots from different organs from PBS-treated and MBPAc1-9(4Y)- 
treated TG4 animals, gated on single, viable CD11b+ cells. Organs from PBS 
controls (A) or MBPAc1-9(4Y)-animals (B) were isolated and stained with a panel of 
antibodies and two subpopulations of MDSCs were identified by flow cytometry. 
Representative of three individual experiments. C) Shown is the frequency of PMN-
MDSCs during EDI after the 3rd and 5th dose of MBPAc1-9(4Y) in various organs 
compared to control mice receiving one dose of PBS. The gating strategy excluded 
dead cells and doublets. Horizontal lines indicate mean. After checking for normality 
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using the Shapiro-Wilk test the Kruskal-Wallis test followed by Dunn’s multiple 
comparison test for data that were not normally distributed was used (* = p ≤ 0.05, ** 
= p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). In the spleen, ILNs, BLNs and lung 
each dot represents one individual mouse. In the liver in some cases cells from two 
animals were combined due to low cell numbers while in the CNS compartment each 
dot represents two individuals. N=6, from two independent experiments. 
Figure 2. Phenotypic analysis of PMN-MDSCs after dose escalation 
immunotherapy. A) Representative flow cytometry plot of splenic PMN-MDSCs from 
MBPAc1-9(4Y)-  (black line) and PBS control-treated (filled grey line) animals after 
gating on viable CD11b+ Ly6G+ cells and comparison of Galectin-9, PD-L1, CD40, 
CD80 and CD86 expression shown as histogram overlays. Dotted line indicates 
negative staining control. B) Bar graph shows mean + SEM. After checking for 
normality using the Shapiro-Wilk test either ANOVA followed by Sidak’s multiple 
comparison test was performed for normally distributed data or the Kruskal-Wallis 
test followed by Dunn’s multiple comparison test for data that were not normally 
distributed (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). Data on the 
left of the vertical line had a normal distribution. In the spleen, ILNs, BLNs and lung 
each bar graph represents six individuals. In the liver in some cases cells from two 
animals were combined due to low cell numbers (n = 4) while in the CNS 
compartment each measurement contained cells from two animals. Kruskal-Wallis 
test followed by Dunn’s multiple comparison test was applied to CD40, CD80 and 
CD86 data. N=6, from two independent experiments. 
Figure 3. Splenic PMN-MDSCs suppress the proliferation of CD4+ T cells in an 
antigen-specific manner. PMN-MDSCs were co-cultured for four days together with 
naïve (Tnaiv) and antigen-experienced T cells (Tag) labelled with cell proliferation 
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dye at a ratio of 1:3 with their cognate peptide and CD11c+ cells used as APCs. 
Gated on single, viable CD4+ T cells. A) Proliferation of Tnaiv and Tag CD4+ T cells 
after culture with or without PMN-MDSCs (n=5). Box shows 25th to 75th percentiles. 
The horizontal line is plotted at the median. Whiskers show Min to Max. Mean is 
shown as a '+'. B) Foxp3 expression in CD4+ Tnaiv and CD4+ Tag after culture with 
or without PMN-MDSC’s (n=5). Box shows 25th to 75th percentiles. The horizontal 
line is plotted at the median. Whiskers show Min to Max. '+' indicates mean. After 
checking for normality using the Shapiro-Wilk test ANOVA followed by Sidak’s 
multiple comparison test was performed for normally distributed data (* = p ≤ 0.05, ** 
= p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). 
Figure 4. Splenic PMN-MDSCs suppress CD4+ T cell proliferation induced by plate-
bound anti-CD3 and anti-CD28 in a cell-contact dependent manner. Naïve (Tnaiv) 
(A) or antigen-experienced CD4+ T cells (Tag) (B) labelled with cell proliferation dye, 
were cultured with PMN-MDSCs from either tolerised (n=6) or PBS-treated mice 
(n=3) on an anti-CD3+antiCD28-coated plate at a ratio of 1:1. C) Splenic, FACS-
sorted PMN-MDSC from tolerised mice and CD4+ Tag cells were cultured together at 
a ratio of 1:1 in on anti-CD3+anti-CD28-coated plate, separated by a membrane 
(n=3). Gated on single, viable CD4+ T cells. Box shows 25th to 75th percentiles. The 
horizontal line is plotted at the median. Whiskers show Min to Max. '+' indicates 
mean. Kruskal-Wallis test followed by Dunn’s multiple comparison test was 
performed for data that were not normally distributed (* = p ≤ 0.05, ** = p ≤ 0.01, *** 
= p ≤ 0.001, **** = p ≤ 0.0001). 
Figure 5. Determination of the mechanism of PMN-MDSCs mediated CD4+ T cell 
suppression in vitro. Splenic, FACS-sorted PMN-MDSC from tolerised mice and 
CD4+ Tag cells were cultured together at a ratio of 1:1 on an anti-CD3+anti-CD28-
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coated plate. A) Antibodies to Galectin-9, PD-L1, CD40, CD80, CD86 and IL-10R 
(10 μg/ml) or B) chemical inhibitors of iNOS (L-NMMA) or arginase-1 (BEC) (both at 
500 μM) were added for the duration of the culture (n = 3 each). Gated on single, 
viable CD4+ T cells. Box shows 25th to 75th percentiles. The horizontal line is plotted 
at the median. Whiskers show Min to Max. '+' indicates mean. Kruskal-Wallis test 
followed by Dunn’s multiple comparison test was performed (* = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). 
Figure 6. Frequencies and phenotype of PMN-MDSCs in peripheral organs in 
diseased versus tolerised mice. Tg4 mice were treated with PBS or MBPAc1-9(4Y)-
EDI before the induction of EAE. Animals were analysed at the peak of disease 
when mice treated with PBS showed complete hind limb paralysis (grade 3) and 
EDI-treated animals showed no sign of disease. A) Shown are single, viable CD11b+ 
Ly6G+ cells. Horizontal lines indicate mean. After checking for normality using the 
Shapiro-Wilk test the unpaired t test was performed for normally distributed data (* = 
p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). Each dot represents one 
individual, n=7-11. Pooled data from three independent experiments. B) Single, 
viable PMN-MDSCs were analysed for the expression of CD40, CD80, Galectin-9 
and PD-L1. Horizontal lines indicate mean. After checking for normality using the 
Shapiro-Wilk test either unpaired t test was performed for normally distributed data 
or the Mann-Whitney U test for data that were not normally distributed (* = p ≤ 0.05, 
** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). Each dot represents one individual, 
n=7-11. Pooled data from three independent experiments. Unpaired t test was 
applied to CNS data. Unpaired t test was applied to Galectin-9 BLN data and PD-L1 
data whereas the Mann-Whitney U test was applied to spleen Galectin-9 data. 
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Figure 7. Splenectomy impairs the increase in the number of PMN-MDSCs post EDI 
and prevents tolerance induction. Tg4 mice underwent either a sham operation or 
splenectomy 14 days before EDI to induce tolerance or PBS only as a control. 
Thereafter, ILNs, BLNs, lungs and liver were removed and analysed by flow 
cytometry (each dot represents an animal), gated on single, viable cells. Horizontal 
lines in A and B indicate mean. After checking for normality using the Shapiro-Wilk 
test either ANOVA followed by Sidak’s multiple comparison test was performed for 
normally distributed data or the Kruskal-Wallis test followed by Dunn’s multiple 
comparison test for data that were not normally distributed (* = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). A) Percentage of CD11b+ Ly6G+ PMN-
MDSCs in the ILN, BLN, lung and liver in splenectomised or sham-operated mice 
that have either been tolerised with MBPAc1-9(4Y) or received control treatment with 
PBS only. ANOVA followed by Sidak’s multiple comparison test was applied to ILN 
(n=6-7, pooled data from 2 independent experiments) and BLN data (n=6-7, pooled 
data from 2 independent experiments). Kruskal-Wallis test followed by Dunn’s 
multiple comparison test was applied to lung and liver data (n=3-4, one experiment). 
B) Absolute numbers of CD11b+ Ly6G+ PMN-MDSCs in the ILN, BLN, lung and liver 
in splenectomised or sham-operated mice that have either been tolerised with 
MBPAc1-9(4Y) or received control treatment with PBS only.  ANOVA followed by 
Sidak’s multiple comparison test was applied to ILN (n=6-7, pooled data from 2 
independent experiments) and BLN data (n=6 -7, pooled data from two independent 
experiments). Kruskal-Wallis test followed by Dunn’s multiple comparison test was 
applied to lung and liver data (n=3-4, one experiment). C) Tg4 mice underwent either 
sham operation or splenectomy 14 days before EDI to induce tolerance or were 
treated with PBS as a control. Subsequently, EAE was induced and animals were 
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monitored daily for 20 days for signs of disease. Line graph shows disease scores 
over time (mean+SEM). Bar graph shows area under the curve (AUC, mean+SEM). 
One-way ANOVA with Tukey’s multiple comparison post hoc test p ≤ 0.05, n=9-12 
for each group, pooled data from three independent experiments, mean+SEM). 
Figure 8. Signalling through the IL-10 receptor is required for PMN-MDSCs 
accumulation. Tg4IL-10-/- mice or wild-type Tg4 mice were either treated with PBS as 
a control or MBPAc1-9(4Y) according to the EDI protocol until the 3rd dose before 
isolating the spleen and lymph nodes to define quantity of PMN-MDSCs. Horizontal 
lines indicate mean. Each dot represents one individual, n=4-6, pooled data from 
three independent experiments. Kruskal-Wallis test followed by Dunn’s multiple 
comparison test was performed for data that were not normally distributed (* = p ≤ 
0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). A) Percentages of CD11b+ 
Ly6G+ PMN-MDSCs in spleen and lymph nodes of PBS or MBPAc1-9(4Y)-treated 
wild-type Tg4 and Tg4IL-10-/- mice, gated on single, viable cells. B) Absolute 
numbers of CD11b+ Ly6G+ PMN-MDSCs in spleen and lymph nodes of PBS or 
MBPAc1-9(4Y)-treated wild-type Tg4 and Tg4IL-10-/- mice. Definition of the phenotype 
of PMN-MDSCs, gated on single, viable CD11b+ Ly6G+ PMN-MDSCs. N=4-6, pooled 
data from two to three independent experiments. Kruskal-Wallis test followed by 
Dunn’s multiple comparison test was performed for data that were not normally 
distributed (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). Bar graph 
shows mean + SEM. C) CD80 expression on CD11b+ Ly6G+ PMN-MDSCs in spleen 
and lymph nodes of PBS or MBPAc1-9(4Y)-treated wild-type Tg4 and Tg4IL-10-/- mice. 
D) CD86 expression on CD11b+ Ly6G+ PMN-MDSCs in spleen and lymph nodes of 
PBS or MBPAc1-9(4Y)-treated wild-type Tg4 and Tg4IL-10-/- mice. 
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Figure 9. Adoptive transfer of PMN-MDSCs reduces CD4+ T cell proliferation after 
antigen prime ex vivo. Tg4 mice received either a cell transfer of 1.5x106 FACS 
sorted PMN-MDSC i.p. or no transfer three days before priming with MBPAc1-9(4K) 
peptide in CFA at the base of the tail. Ten days post-prime, spleen and ILNs were 
harvested and a 3[H]-Thymidine assay set up. A) Proliferative response of whole cell 
isolates from the spleen and ILN, after restimulation in vitro with titrated doses of 
MBPAc1-9(4K) (n = 6 - 8, pooled data from two independent experiments). Line graph 
shows mean ± SEM. After checking for normality using the Shapiro-Wilk test the 
unpaired t test was performed for normally distributed data (* = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). B) Proliferative response of magnetically 
isolated CD4+ T cells from the spleen and ILN, after restimulation in vitro with titrated 
doses of MBPAc1-9(4K) in the presence of irradiated APCs (n = 3). Mann-Whitney U 
test (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001) C) ICCS of isolated 
single, viable CD4+ T cells from spleen and lymph nodes. Each dot represents one 
individual (n=3). Horizontal lines indicate mean. (Mann-Whitney U test). 
Figure 10. PMN-MDSCs limit the encephalogenicity of Th1 cells. Tg4 mice received 
an adoptive transfer of 5x106 Th1 cells that were differentiated in vitro in the presence 
(PMN-MDSC-Th1) or absence of PMN-MDSCs (Th1) (n=5 per group). Line graph 
and bar graph show mean + SEM. Mann-Whitney U test was performed for 
comparison of mean EAE score of individual days. Unpaired t-test with Welch’s 
correction was used for the comparison of AUCs. (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p 
≤ 0.001, **** = p ≤ 0.0001). 
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Table 1. PMN-MDSCs limit the encephalogenicity of Th1 cells. Tg4 mice received an 
adoptive transfer of 5x106 Th1 cells that were differentiated in vitro in the presence 
(PMN-MDSC-Th1) or absence of PMN-MDSCs (n=5 per group). * Day of onset is the 
first day mice showed signs of EAE after cell transfer. † Incidence is the number of 
cases of EAE/number of mice immunized for each group.  
treatment day of 
onset* 
mean ± 
SEM 
incidence† maximum 
score 
mean ± SEM 
area under 
the curve 
mean ± 
SEM 
polarised under normal Th1 conditions  
Th1 6.8 ± 0.86 5/5 3 ± 0.54 32.6 ± 0.92 
Th1 cells polarised under PMN-MDSCs influence 
PMN-MDSC-Th1 5.8 ± 0.36 5/5 2 ± 0 15.2 ± 0.27 
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